2002
Circulating Levels of Interleukin-6 Soluble Receptor Predict Rates of Bone Loss in Patients with Primary Hyperparathyroidism
Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K. Circulating Levels of Interleukin-6 Soluble Receptor Predict Rates of Bone Loss in Patients with Primary Hyperparathyroidism. The Journal Of Clinical Endocrinology & Metabolism 2002, 87: 4946-4951. PMID: 12414855, DOI: 10.1210/jc.2001-011814.Peer-Reviewed Original ResearchConceptsBone lossIL-6sRTotal femurIL-6IL-6 soluble receptorPrimary hyperparathyroidism resultsYearly bone lossSubset of patientsUntreated hyperparathyroidismDisease activityPrimary hyperparathyroidismUpper tertileCytokine axisHyperparathyroidismSoluble receptorPatientsBiochemical markersClassical biochemical markersWhole groupFemurPredict rateGreater rateRecent studiesTertileGroup
1991
Treatment of Sarcoidosis-Associated Hypercalcemia With Ketoconazole
Bia M, Insogna K. Treatment of Sarcoidosis-Associated Hypercalcemia With Ketoconazole. American Journal Of Kidney Diseases 1991, 18: 702-705. PMID: 1962657, DOI: 10.1016/s0272-6386(12)80613-5.Peer-Reviewed Original ResearchConceptsAngiotensin-converting enzyme levelsACE levelsSide effectsLong-term side effectsDihydroxyvitamin D levelsLiver function testsSymptom-free intervalSerum ACE levelsSerum testosterone levelsSerum cortisol levelsLong-term usePatient's hypercalcemiaCorticosteroid treatmentDisease activityKetoconazole therapySerum creatinineFunction testsPersistent elevationD levelsRapid recurrenceCalcium metabolismKetoconazole treatmentTestosterone levelsHypercalcemiaLarge dose